[{"address1": "Jinchuang Plaza", "address2": "Building 1, Fourth Floor 4560 Jinke Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 6163 2588", "website": "https://www.zailaboratory.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00efve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Ying  Du Ph.D.", "age": 58, "title": "Founder, Chairperson & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1698822, "exercisedValue": 11985000, "unexercisedValue": 57389912}, {"maxAge": 1, "name": "Mr. Joshua L.  Smiley", "age": 54, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1223640, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rafael G.  Amado M.D.", "age": 60, "title": "President and Head of Global Research & Development", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1601060, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yajing  Chen Ph.D.", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 624562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Huang Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Chiou", "title": "Senior VP & Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frazor Titus  Edmondson III, J.D.", "age": 58, "title": "Chief Legal Officer & Joint Corporate Secretary", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 829003, "exercisedValue": 0, "unexercisedValue": 4122300}, {"maxAge": 1, "name": "Dr. Jonathan J.  Wang MBA, Ph.D.", "age": 42, "title": "Chief Business Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Yan DABT, M.D., Ph.D.", "age": 60, "title": "Chief Operating Officer of R&D", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tong  Zhu", "age": 46, "title": "Chief Commercial Officer of Greater China", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 34.38, "open": 32.29, "dayLow": 32.29, "dayHigh": 34.955, "regularMarketPreviousClose": 34.38, "regularMarketOpen": 32.29, "regularMarketDayLow": 32.29, "regularMarketDayHigh": 34.955, "payoutRatio": 0.0, "forwardPE": -18.136126, "volume": 1407188, "regularMarketVolume": 1407188, "averageVolume": 761303, "averageVolume10days": 1565660, "averageDailyVolume10Day": 1565660, "bid": 34.55, "ask": 35.0, "bidSize": 14, "askSize": 14, "marketCap": 3750680576, "fiftyTwoWeekLow": 13.48, "fiftyTwoWeekHigh": 36.6, "priceToSalesTrailing12Months": 9.400485, "fiftyDayAverage": 27.4992, "twoHundredDayAverage": 23.4725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 36811304960, "profitMargins": -0.64439005, "floatShares": 987576215, "sharesOutstanding": 108276000, "sharesShort": 7577556, "sharesShortPriorMonth": 6051368, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.0696, "heldPercentInsiders": 0.01502, "heldPercentInstitutions": 0.54036, "shortRatio": 12.92, "shortPercentOfFloat": 0.0791, "impliedSharesOutstanding": 98838704, "bookValue": 7.803, "priceToBook": 4.439318, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -257103008, "trailingEps": -2.6, "forwardEps": -1.91, "enterpriseToRevenue": 92.262, "enterpriseToEbitda": -136.207, "52WeekChange": 0.68364346, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 34.64, "targetHighPrice": 74.0, "targetLowPrice": 29.0, "targetMeanPrice": 52.435, "targetMedianPrice": 51.955, "recommendationMean": 1.27273, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 779667008, "totalCashPerShare": 0.721, "ebitda": -270260992, "totalDebt": 153471008, "quickRatio": 2.903, "currentRatio": 3.509, "totalRevenue": 398988000, "debtToEquity": 18.251, "revenuePerShare": 4.032, "returnOnAssets": -0.1587, "returnOnEquity": -0.31410998, "grossProfits": 251128000, "freeCashflow": -400692864, "operatingCashflow": -214868992, "revenueGrowth": 0.657, "grossMargins": 0.62941, "ebitdaMargins": -0.67737, "operatingMargins": -0.62245, "financialCurrency": "USD", "symbol": "ZLAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1740787355, "regularMarketTime": 1740776400, "exchange": "NGM", "messageBoardId": "finmb_271123063", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Zai Lab Limited", "longName": "Zai Lab Limited", "marketState": "CLOSED", "regularMarketChangePercent": 0.7562487, "regularMarketPrice": 34.64, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1505914200000, "postMarketChangePercent": 2.45382, "postMarketPrice": 35.49, "postMarketChange": 0.850002, "regularMarketChange": 0.25999832, "regularMarketDayRange": "32.29 - 34.955", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 761303, "fiftyTwoWeekLowChange": 21.16, "fiftyTwoWeekLowChangePercent": 1.569733, "fiftyTwoWeekRange": "13.48 - 36.6", "fiftyTwoWeekHighChange": -1.9599991, "fiftyTwoWeekHighChangePercent": -0.05355189, "fiftyTwoWeekChangePercent": 68.36435, "earningsTimestamp": 1740663000, "earningsTimestampStart": 1746561600, "earningsTimestampEnd": 1747080000, "earningsCallTimestampStart": 1740661200, "earningsCallTimestampEnd": 1740661200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.6, "epsForward": -1.91, "epsCurrentYear": -1.76274, "priceEpsCurrentYear": -19.651224, "fiftyDayAverageChange": 7.1407986, "fiftyDayAverageChangePercent": 0.25967294, "twoHundredDayAverageChange": 11.1675, "twoHundredDayAverageChangePercent": 0.4757695, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Zai Lab", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]